Tomsk National Research Medical Center Researchers Yield New Data on Endometrial Cancer (Predicting Response to Immunotargeted Therapy in Endometrial Cancer via Tumor Immune Microenvironment: A Multicenter, Observational Study).

A study conducted at the Tomsk National Research Medical Center in Russia has found that only one-third of patients with advanced MSS/pMMR endometrial cancer respond well to the combination treatment of Pembrolizumab and Lenvatinib. The researchers analyzed tumor samples from 28 patients and found that the proportion of CD20+ B lymphocytes and the CD8-to-CD20 lymphocytes ratio were significantly higher in patients who responded to treatment compared to non-responders. These biomarkers can serve as prognostic markers for response to immunotargeted therapy and progression-free survival in patients with endometrial cancer. Further research is needed to explore tumor microenvironment parameters and identify accurate markers for this type of therapy. [Extracted from the article]